Analyst Alec Stranahan from Bank of America Securities maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) and keeping the price target at $79.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Alec Stranahan has given his Buy rating due to a combination of factors including the promising potential of Crispr Therapeutics AG’s in vivo gene editing approach. The company’s updated timeline for the CTX320 asset, targeting Lp(a), aligns well with the expected outcomes from the HORIZON trial, providing a clearer picture of the impact on functional outcomes. This alignment offers a significant opportunity for value creation if the results are positive.
Additionally, the updated data for CTX310, targeting ANGPTL3, shows competitive reductions in triglycerides and LDL, with a strong safety profile, reinforcing confidence in the company’s approach. The continued interest in gene editing, as evidenced by recent industry acquisitions, highlights the potential for further business development opportunities for Crispr Therapeutics AG. The company’s diverse and robust pipeline, along with its strategic positioning, supports the Buy rating with a price objective of $79.
In another report released yesterday, Chardan Capital also reiterated a Buy rating on the stock with a $82.00 price target.